tiprankstipranks
Trending News
More News >
Roivant Sciences (ROIV)
NASDAQ:ROIV
Advertisement

Roivant Sciences (ROIV) AI Stock Analysis

Compare
655 Followers

Top Page

ROIV

Roivant Sciences

(NASDAQ:ROIV)

Rating:48Neutral
Price Target:
$11.50
▼(-1.20% Downside)
Roivant Sciences' overall stock score is primarily impacted by its financial performance, which shows significant challenges with declining revenues and persistent losses. While technical indicators suggest a neutral to slightly bullish trend, the negative valuation metrics highlight concerns about the stock's current pricing. The positive sentiment from the earnings call and corporate events, such as the share repurchase program, provide some optimism but are not enough to offset the financial difficulties.
Positive Factors
Drug Development
Brepocitinib is nicely positioned as an oral therapy to be used ahead of biologics and cell therapy, even if those potentially offer improved efficacy.
Financial Performance
ROIV ended the quarter with $4.5B in consolidated cash, cash equivalents, restricted cash, and marketable securities.
Share Repurchase Program
The company completed its $1.5B share repurchase program, reducing outstanding shares by over 15% since March 31, 2024.
Negative Factors
Clinical Trial Risks
The trial carries some risks due to the lack of randomized experience with brepocitinib in the indication.
Competition
There is increasing competition in Graves' disease and thyroid eye disease, with novel therapies being developed by other companies.

Roivant Sciences (ROIV) vs. SPDR S&P 500 ETF (SPY)

Roivant Sciences Business Overview & Revenue Model

Company DescriptionRoivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, warm autoimmune hemolytic anemia, thyroid eye diseases, sarcoidosis, and staph aureus bacteremia. The company was founded in 2014 and is based in London, the United Kingdom.
How the Company Makes MoneyRoivant Sciences makes money primarily through the development and commercialization of pharmaceutical products. The company generates revenue by advancing its drug candidates through clinical trials and obtaining regulatory approval for their sale. Roivant may also earn income through licensing agreements, partnerships, and collaborations with other pharmaceutical companies, where they might receive upfront payments, milestone-based payments, and royalties on sales. Additionally, Roivant's unique business model of creating Vants allows for the potential monetization of these subsidiaries through mergers, acquisitions, or public offerings, contributing further to their financial growth.

Roivant Sciences Earnings Call Summary

Earnings Call Date:Aug 11, 2025
(Q1-2025)
|
% Change Since: 1.31%|
Next Earnings Date:Nov 17, 2025
Earnings Call Sentiment Positive
The earnings call reflects a positive overall sentiment with significant progress in the pipeline, particularly with the upcoming brepocitinib data, a strong financial position, and strategic share repurchase programs. However, challenges remain with ongoing LNP litigation and complexities in clinical trial management.
Q1-2025 Updates
Positive Updates
Upcoming Brepocitinib Data
Brepocitinib, a drug with a well-established safety profile in over 1,500 patients, is approaching a pivotal trial data release that could redefine the standard of care for dermatomyositis (DM).
Share Repurchase Program
Completed a $1.5 billion share repurchase program, reducing share count by over 15%. An additional $500 million repurchase program has been authorized.
Strong Financial Position
Roivant holds $4.5 billion in cash with no debt, providing a strong financial position for future growth and development.
Pipeline Progress
Significant progress across the pipeline, including multiple registrational trials for IMVT-1402 and rapid advancement of brepocitinib in various indications.
Negative Updates
LNP Litigation Ongoing
Roivant is involved in ongoing LNP litigation with Moderna and Pfizer, with a trial scheduled for March 2026 and major international hearings expected in the first half of next year.
Challenges in Managing Steroid Taper
The DM study features a steroid taper which presents challenges in managing placebo patients and ensuring correct protocol adherence.
Company Guidance
In the Roivant First Quarter 2025 earnings call, CEO Matt Gline provided guidance on several key developments and metrics. The company highlighted three main themes for 2025, focusing on the progress with IMVT-1402 and Immunovant, the upcoming data from the pivotal trial of brepocitinib, and ongoing litigation with Moderna. Roivant has completed the last patient visit for the brepocitinib trial, with data expected in the second half of the year, potentially leading to a commercial launch. The company has also been active in share repurchase, completing a $1.5 billion program and authorizing an additional $500 million. Financially, Roivant reported an adjusted net loss of $170 million, with cash utilization of $200 million outside of the share repurchase program, and maintains a strong balance sheet with $4.5 billion in cash and no debt as of June 30, 2025. Roivant is preparing for a potential commercial launch in dermatomyositis (DM) and continues to advance its pipeline, with multiple registrational trials ongoing.

Roivant Sciences Financial Statement Overview

Summary
Roivant Sciences faces significant financial challenges with declining revenues, sustained losses, and negative cash flows. Despite a strong equity position, the company's profitability and cash generation are under pressure, raising concerns about long-term viability without strategic changes or improved operational efficiency.
Income Statement
45
Neutral
Roivant Sciences shows significant volatility in revenue with a declining trend from 2020 to 2025. The company has faced substantial EBIT and net income losses consistently, indicating operational challenges. Gross Profit Margin has been positive, but high EBIT and EBITDA losses reflect underlying inefficiencies.
Balance Sheet
55
Neutral
The company's balance sheet highlights a strong equity position relative to debt, with total debt significantly lower than equity. However, the company's continuous negative net income impacts return on equity. The equity ratio is high, suggesting financial stability, but the persistent losses pose a risk.
Cash Flow
50
Neutral
Roivant Sciences demonstrates weak cash flow management with consistently negative operating and free cash flows. Although investments have been substantial, operational cash flow remains negative, and free cash flow shows no growth, indicating challenges in converting revenue into cash.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue23.23M29.05M124.80M61.28M55.29M23.80M
Gross Profit21.00M28.14M96.83M48.15M46.32M21.74M
EBITDA-981.34M-674.26M4.31B-1.18B-916.71M-895.74M
Net Income-490.63M-171.98M4.35B-1.01B-845.26M-809.23M
Balance Sheet
Total Assets5.03B5.44B7.22B2.39B2.59B2.69B
Cash, Cash Equivalents and Short-Term Investments4.50B4.89B6.54B1.68B2.06B2.13B
Total Debt99.69M100.17M499.75M481.40M283.89M244.98M
Total Liabilities216.70M249.74M773.95M782.02M523.70M527.69M
Stockholders Equity4.35B4.69B5.97B1.16B1.66B1.80B
Cash Flow
Free Cash Flow-858.67M-844.05M-766.65M-856.08M-695.16M-557.94M
Operating Cash Flow-851.00M-839.45M-765.27M-843.39M-677.73M-552.14M
Investing Cash Flow-2.85B-1.77B5.20B-44.27M303.30M-31.70M
Financing Cash Flow-746.95M-1.22B419.36M499.46M306.79M456.26M

Roivant Sciences Technical Analysis

Technical Analysis Sentiment
Positive
Last Price11.64
Price Trends
50DMA
11.46
Positive
100DMA
11.11
Positive
200DMA
11.17
Positive
Market Momentum
MACD
0.11
Negative
RSI
55.78
Neutral
STOCH
48.75
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ROIV, the sentiment is Positive. The current price of 11.64 is above the 20-day moving average (MA) of 11.64, above the 50-day MA of 11.46, and above the 200-day MA of 11.17, indicating a bullish trend. The MACD of 0.11 indicates Negative momentum. The RSI at 55.78 is Neutral, neither overbought nor oversold. The STOCH value of 48.75 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ROIV.

Roivant Sciences Risk Analysis

Roivant Sciences disclosed 98 risk factors in its most recent earnings report. Roivant Sciences reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Roivant Sciences Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
79
Outperform
$8.40B16.41179.14%34.97%71.10%
64
Neutral
$7.47B15.58-10.84%4.52%-205.13%
58
Neutral
$9.04B35.68%7.62%-55.29%
56
Neutral
$9.19B-36.30%3421.98%49.62%
51
Neutral
$7.78B-0.06-40.08%2.29%21.32%-1.82%
51
Neutral
$6.39B-29.70%75.01%-13.20%
48
Neutral
$8.14B1.93-15.84%-85.32%-111.82%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
ROIV
Roivant Sciences
11.64
-0.36
-3.00%
HALO
Halozyme
72.93
8.51
13.21%
JAZZ
Jazz Pharmaceuticals
124.59
8.22
7.06%
MDGL
Madrigal Pharmaceuticals
424.86
174.07
69.41%
BBIO
BridgeBio Pharma
48.87
23.97
96.27%
LEGN
Legend Biotech
35.08
-21.58
-38.09%

Roivant Sciences Corporate Events

Stock Buyback
Roivant Sciences Announces $500M Share Repurchase Program
Positive
Jun 25, 2025

Roivant Sciences Ltd. has announced a new common share repurchase program on June 24, 2025, allowing for the repurchase of up to $500 million of its common shares. This initiative follows a previous $1.5 billion repurchase program from April 2024, which has been fully utilized. The repurchase will be funded with available cash, with no set expiration date, and will depend on market conditions and other factors.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Aug 20, 2025